Standard dose oxcarbazepine — Competitive Intelligence Brief

Standard dose oxcarbazepine (Standard dose oxcarbazepine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticonvulsant; sodium channel blocker. Area: Neurology.

marketed Anticonvulsant; sodium channel blocker Voltage-gated sodium channels Neurology Small molecule

Target snapshot

Standard dose oxcarbazepine (Standard dose oxcarbazepine) — Mario Negri Institute for Pharmacological Research. Oxcarbazepine blocks voltage-gated sodium channels in neuronal membranes, reducing repetitive neuronal firing and stabilizing hyperexcited neural tissue.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Standard dose oxcarbazepine TARGET	Standard dose oxcarbazepine	Mario Negri Institute for Pharmacological Research	marketed	Anticonvulsant; sodium channel blocker	Voltage-gated sodium channels
Buffered Articaine Hydrochloride + Epinephrine	Buffered Articaine Hydrochloride + Epinephrine	Ohio State University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
Articaine Hydrochloride + Epinephrine	Articaine Hydrochloride + Epinephrine	Ankara Yildirim Beyazıt University	marketed	Local anesthetic with vasoconstrictor	Voltage-gated sodium channels; alpha-1 adrenergic receptors (epinephrine component)
Ropivacaine + Ketamine	Ropivacaine + Ketamine	Aga Khan University	marketed	Local anesthetic + NMDA receptor antagonist combination	Voltage-gated sodium channels (ropivacaine); NMDA receptor (ketamine)
Paroxetine+Lamotrigine	Paroxetine+Lamotrigine	Ministry of Health & Welfare, Korea	marketed	SSRI + anticonvulsant mood stabilizer combination	Serotonin transporter (SERT); voltage-gated sodium channels; glutamate release modulation
Dose of prilocaine	Dose of prilocaine	Hospital General Universitario Gregorio Marañon	marketed	Local anesthetic (amide class)	Voltage-gated sodium channels
Levobupivacaine wound infusion	Levobupivacaine wound infusion	University of Genova	marketed	Local anesthetic	Voltage-gated sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticonvulsant; sodium channel blocker class)

1. Korean Epilepsy Society · 1 drug in this class
2. Mario Negri Institute for Pharmacological Research · 1 drug in this class
3. Teva Pharmaceuticals USA · 1 drug in this class